Celltrion Pharm, Inc. (068760.KQ)
KRW 48700.0
(1.35%)
KRW 48700.0
(1.35%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 80.93 Billion KRW | 10.14% |
| 2022 | 73.48 Billion KRW | 4.29% |
| 2021 | 70.46 Billion KRW | 46.6% |
| 2020 | 48.06 Billion KRW | 4.32% |
| 2019 | 46.07 Billion KRW | 27.61% |
| 2018 | 36.1 Billion KRW | -25.44% |
| 2017 | 48.42 Billion KRW | -13.19% |
| 2016 | 55.77 Billion KRW | 37.18% |
| 2015 | 40.66 Billion KRW | 117446.22% |
| 2014 | 34.59 Million KRW | 12.17% |
| 2013 | 30.83 Million KRW | 9.97% |
| 2012 | 28.04 Million KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 19.3 Billion KRW | -6.3% |
| 2024 Q2 | 19.17 Billion KRW | -0.69% |
| 2023 Q3 | 21.97 Billion KRW | 8.43% |
| 2023 Q4 | 20.6 Billion KRW | -6.24% |
| 2023 FY | 80.93 Billion KRW | 10.14% |
| 2023 Q1 | 18.08 Billion KRW | 0.15% |
| 2023 Q2 | 20.26 Billion KRW | 12.08% |
| 2022 FY | 73.48 Billion KRW | 4.29% |
| 2022 Q4 | 18.05 Billion KRW | -10.57% |
| 2022 Q1 | 17.27 Billion KRW | -24.55% |
| 2022 Q3 | 20.19 Billion KRW | 12.42% |
| 2022 Q2 | 17.95 Billion KRW | 3.94% |
| 2021 Q3 | 16.72 Billion KRW | 4.25% |
| 2021 Q4 | 22.89 Billion KRW | 36.95% |
| 2021 Q2 | 16.03 Billion KRW | 8.35% |
| 2021 Q1 | 14.8 Billion KRW | 105536.97% |
| 2021 FY | 70.46 Billion KRW | 46.6% |
| 2020 Q3 | 11.39 Million KRW | 4.82% |
| 2020 FY | 48.06 Billion KRW | 4.32% |
| 2020 Q4 | 14.01 Million KRW | 22.96% |
| 2020 Q2 | 10.87 Million KRW | -11.34% |
| 2020 Q1 | 12.26 Million KRW | -11.57% |
| 2019 FY | 46.07 Billion KRW | 27.61% |
| 2019 Q3 | 11.84 Million KRW | -4.55% |
| 2019 Q1 | 10.3 Million KRW | -23.72% |
| 2019 Q4 | 13.86 Million KRW | 17.08% |
| 2019 Q2 | 12.41 Million KRW | 20.47% |
| 2018 Q2 | 9.56 Million KRW | 15.71% |
| 2018 FY | 36.1 Billion KRW | -25.44% |
| 2018 Q1 | 8.27 Million KRW | 174.05% |
| 2018 Q4 | 13.5 Million KRW | 36.03% |
| 2018 Q3 | 9.92 Million KRW | 3.75% |
| 2017 Q1 | 9.34 Million KRW | -63.18% |
| 2017 Q2 | 12.62 Million KRW | 35.17% |
| 2017 FY | 48.42 Billion KRW | -13.19% |
| 2017 Q4 | 3.01 Million KRW | -75.38% |
| 2017 Q3 | 12.25 Million KRW | -2.95% |
| 2016 Q3 | 10.72 Million KRW | -8.62% |
| 2016 FY | 55.77 Billion KRW | 37.18% |
| 2016 Q1 | 9.13 Million KRW | -69.84% |
| 2016 Q2 | 11.73 Million KRW | 28.53% |
| 2016 Q4 | 25.37 Million KRW | 136.62% |
| 2015 Q3 | 10.92 Million KRW | -1.48% |
| 2015 Q2 | 11.08 Million KRW | 21.92% |
| 2015 Q1 | 9.09 Million KRW | 16.13% |
| 2015 FY | 40.66 Billion KRW | 117446.22% |
| 2015 Q4 | 30.27 Million KRW | 177.18% |
| 2014 Q3 | 10.58 Million KRW | 8.2% |
| 2014 FY | 34.59 Million KRW | 12.17% |
| 2014 Q4 | 7.83 Million KRW | -26.01% |
| 2014 Q2 | 9.78 Million KRW | 52.88% |
| 2014 Q1 | 6.39 Million KRW | -19.74% |
| 2013 Q3 | 6.76 Million KRW | -22.54% |
| 2013 FY | 30.83 Million KRW | 9.97% |
| 2013 Q1 | 7.36 Million KRW | -3.39% |
| 2013 Q4 | 7.97 Million KRW | 17.82% |
| 2013 Q2 | 8.73 Million KRW | 18.51% |
| 2012 Q4 | 7.62 Million KRW | 0.0% |
| 2012 FY | 28.04 Million KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 102.52 Billion KRW | 21.059% |
| CMG Pharmaceutical Co., Ltd. | 37.86 Billion KRW | -113.741% |
| Huons Global Co., Ltd. | 294.87 Billion KRW | 72.553% |
| DongKook Pharmaceutical Co., Ltd. | 338.16 Billion KRW | 76.066% |
| Enzychem Lifesciences Corporation | 18.7 Billion KRW | -332.716% |
| Humedix Co., Ltd. | 33.04 Billion KRW | -144.939% |
| Boditech Med Inc. | 47.05 Billion KRW | -72.015% |
| EuBiologics Co., Ltd. | 24.95 Billion KRW | -224.265% |
| FutureChem Co.,Ltd | 9.16 Billion KRW | -782.991% |
| Huons Co., Ltd. | 226.14 Billion KRW | 64.21% |
| BNC Korea Co., Ltd. | 25.19 Billion KRW | -221.19% |
| AptaBio Therapeutics Inc. | 16.45 Billion KRW | -391.954% |